Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chest injection may lower anesthetic doses during heart surgery

NCT ID NCT03734159

Symptom relief Sponsor: CMC Ambroise Paré Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a parasternal block—an injection of the numbing drug ropivacaine into the chest wall—could reduce the amount of anesthetic needed to keep heart rate and blood pressure stable during coronary artery bypass surgery. Thirty-five patients were randomly assigned to receive either ropivacaine or a placebo before surgery. The goal was to see if the block could prevent dangerous spikes in heart rate and blood pressure without requiring high doses of anesthetics.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ropivacaine
What this could lead to
If it works, this could lead to a simple injection that reduces the amount of strong anesthetics needed during heart surgery, potentially improving safety.
What could go wrong
This is a small, completed Phase 4 trial with only 35 participants, so results may not apply to all patients. The block may not work as well in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

35 people

The number who actually took part.

Started

Dec 2018

Finished

Nov 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing coronary artery bypass graft requiring sternotomy other than re-interventions and combined surgeries * Consent for participation * Affiliation to the french social security system Exclusion Criteria: * Pregnant or breastfeeding women * Patients under protection of the adults (guardianship, curator or safeguard of justice) * Communication difficulties or neuropsychiatric disorder * Neuropathic disease * Constitutional coagulation disorders * Kidney insufficiency * Sensitivity to nonsteroidal anti-inflammatory drugs * Hypersensitivity to local anaesthetics * Chronic use of opioid analgesics * Corticosteroid treatment or immunosuppressive therapy * Autoimmune disease * Chronic pain syndrome or fibromyalgia * Emergency cardiac surgery * Hypovolemia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder coronary restenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary bypass graft stenosis

Contacts and locations

Locations

  • CMC Ambroise Paré

    Neuilly-sur-Seine, Île-de-France Region, 92200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.